42.53  -0.92 (-2.12%)		09-15 16:00
Open: 42.725 High: 42.93 Volume: 8,802,801		Pre. Close: 43.45 Low: 42.405 Market Cap: 188,859(M)

Short term
Mid term
Targets	6-month :	54.04	1-year :	56.83
Resists	First :	46.27	Second :	48.65
Pivot price	45.45
Supports	First :	42.4	Second :	35.28
MAs	MA(5) :	43.52	MA(20) :	45.69
	MA(100) :	45.52	MA(250) :	46.2
MACD	MACD :	-0.9	Signal :	-0.6
%K %D	K(14,3) :	6.7	D(3) :	5
RSI	RSI(14): 35.7
52-week	High :	61.1	Low :	34.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NVO ] has closed above bottom band by 6.6%. Bollinger Bands are 15.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	43.05 - 43.29	43.29 - 43.48
Low:	41.66 - 42	42 - 42.28
Close:	42.03 - 42.53	42.53 - 42.95

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Tue, 15 Sep 2026
Novo CEO seeks a more consumer-centric culture (NVO:NYSE) - Seeking Alpha

Tue, 15 Sep 2026
Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption - 24/7 Wall St.

Tue, 15 Sep 2026
Novo Nordisk Stock Falls After Major Rebrand - Yahoo Finance

Tue, 15 Sep 2026
Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why - TipRanks

Tue, 15 Sep 2026
Novo Nordisk (NYSE: NVO) has repurchased 33,084,179 shares - Stock Titan

Mon, 14 Sep 2026
NVO Stock Alert: What to Know as Novo Nordisk Rebrands to 'Novo' - Barchart.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	3,350 (M)
Shares Float	3,170 (M)
Held by Insiders	0 (%)
Held by Institutions	9.8 (%)
Shares Short	33,830 (K)
Shares Short P.Month	31,090 (K)

EPS	4.07
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.73
Profit Margin	35.3 %
Operating Margin	42.5 %
Return on Assets (ttm)	18.7 %
Return on Equity (ttm)	59.8 %
Qtrly Rev. Growth	2 %
Gross Profit (p.s.)	80.62
Sales Per Share	98.33
EBITDA (p.s.)	51.84
Qtrly Earnings Growth	-20.7 %
Operating Cash Flow	131,880 (M)
Levered Free Cash Flow	37,670 (M)

PE Ratio	10.44
PEG Ratio	3.3
Price to Book value	5.49
Price to Sales	0.43
Price to Cash Flow	1.08

Dividend	0.57
Forward Dividend	0
Dividend Yield	1.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.